Beltran Lab

You are here

News

ASCO 2017: Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer informs tumor heterogeneity
Chicago, IL (UroToday.com) The authors of this study previously published a manuscript identifying the divergent clonal evolution of castration-resistant prostate cancer (CRPC) to a neuroendocrine prostate cancer histology (NEPC).1
ASCO 2017: Rovalpituzumab tesirine as a therapeutic agent for Neuroendocrine Prostate Cancer

Chicago, IL (UroToday.com) Neuroendocrine prostate cancer (NEPC) represents a rare subtype of prostate cancer. NEPC represent a histologic subtype of prostate cancer that demonstrate low to absent AR expression and often have neuroendocrine features, and thus have low PSA production.

Department of Defense Impact Award Funds Prostate Cancer Study